Kamada

KMDA · NASDAQ

$7.85+$0.24 (+3.15%)TodayMarket closed ·
Prev close $7.61

About KMDA

Kamada Ltd. is a biopharmaceutical company, which focuses on specialty plasma-derived therapeutic. The company is headquartered in Rehovot, Central(Hamerkaz) and currently employs 393 full-time employees. The company went IPO on 2005-08-01. The firm uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.

Employees
462
Headquarters
Rehovot, Central(HaMerkaz)
Listed
Aug 1, 2005
Sector
Health Care
Industry
Biotechnology
Website
kamada.com

Leadership

Kamada executives
NameTitleSince
Lilach Asher Topilsky—2020
Amir London——
David Tsur—2015
Chaime Orlev——
Ruth Wolfson——
Barak Bashari——
Nir Livneh——
Shani Dotan——
Yael Brenner——
Orit Pinchuk——
Eran Schenker——
Michal Stein——
Pnina Strauss——
Naveh Tov——
Michal Ayalon——
Eitan Kyiet——
Michael Berelowitz——
Jonathan Hahn——
Itzhak Krinsky——
Gwen Melincoff——
Leon Recanati—2005
Shmuel Rubinstein——
Prof. Ari Shamiss——
Estery Giloz-Ran——
Abraham Havron——
Tuvia Shoham——

Revenue by product and region

Fiscal year ended Dec 31, 2021: $103.64M total revenue

By product

  • Proprietary Products [Member]$75.52M72.9%
  • Distribution [Member]$28.12M27.1%

By region

  • U.S.A and North America [Member]$49.76M48.0%
  • Israel [Member]$35.77M34.5%
  • Latin America [Member]$9.13M8.8%
  • Europe [Member]$5.68M5.5%
  • Asia [Member]$3.17M3.1%
  • Others [Member]$134.00K0.1%

Similar companies

Companies in the same industry as Kamada

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.